We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





AACC’s Disruptive Technology Award to Highlight Developers of AI and ML Technologies Advancing Medicine and Pathology

By LabMedica International staff writers
Posted on 31 Aug 2021
Three finalists will compete live at the Disruptive Technology Award session at the 2021 American Association for Clinical Chemistry (AACC; Washington, DC, USA) Annual Scientific Meeting and a winner will be selected and announced at the conclusion of the session.

AACC's Disruptive Technology Award Competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. More...
It provides an opportunity for early to mid-stage start-ups in the medical device, diagnostic, or digital health/health IT spaces to showcase their technology and present to a large audience and a panel of judges. The 2021 Disruptive Technology Award finalists and their disruptive technologies include Day Zero Diagnostics, Inc. — DZD OneSeq Dx; Mammoth Biosciences — DETECTR; and MeMed — MeMed COVID-19 Severity.

The first finalist, Day Zero Diagnostics has developed a set of breakthrough capabilities that can provide a complete diagnosis of bloodstream infections and sepsis, including both the species ID and antibiotic susceptibility profile, in hours vs. days. Its technology enables the unprecedented recovery of pathogen whole genome sequences directly from clinical samples that may contain up to a billion times more human DNA. The company’s algorithms then interpret the genomic data to provide accurate, comprehensive organism ID and antibiotic susceptibility profiles. Day Zero Diagnostics enables a targeted treatment on day zero of hospital admission, resulting in better patient outcomes and cost savings.

The second finalist, Mammoth Biosciences has catalyzed a new approach to molecular diagnostics, called DETECTR. Based on CRISPR, this programmable platform acts as a search engine for biology and is capable of finding and identifying any nucleic acid sequence in the genome. Using proprietary technology licensed exclusively from the University of California, Berkeley and developed internally, Mammoth is working on multiple form factors and test targets from infectious diseases to cancer. For example, DETECTR was configured in less than two weeks to detect SARS-CoV-2, demonstrating the platform’s ability to be quickly tailored to identify any DNA or RNA target. The resulting product, DETECTR BOOST, is a reagent kit that when combined with standard laboratory automation provides labs with unparalleled high throughput molecular testing.

The third finalist, MeMed BV’s lead product accurately differentiates bacterial from viral (BV) infection, enabling improved patient management, including appropriate antibiotic use, in order to help address the global healthcare challenge of antimicrobial resistance. Based on computational integration of bacterial and viral-responsive immune proteins, Key delivers the BV result in 15 minutes from serum. This test was clinically validated on thousands of patients, is CE-marked and 510(k) pending.

The three finalists will present data on their technology in a special session during the Annual Scientific Meeting. During this session, a panel of expert judges will evaluate all presented testing solutions based on feasibility and performance. The audience will also vote for their favorite technology.

Related Links:
American Association for Clinical Chemistry


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)
ADLM

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.